Cargando…

Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): Results From a Double-Blind, Placebo-Controlled, Randomized Withdrawal Study

Endogenous Cushing’s syndrome (CS) is a rare, serious disorder caused by chronic cortisol excess. A phase 3, open-label study (SONICS) demonstrated efficacy and safety of levoketoconazole in adults with CS. LOGICS is a phase 3, double-blind (DB), placebo-controlled, randomized-withdrawal (R-W) study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zacharieva, Sabina, Pivonello, Rosario, Elenkova, Atanaska, Toth, Miklos, Shimon, Ilan, Stigliano, Antonio, Badiu, Corin P, Brue, Thierry Christian, Georgescu, Carmen Emanuela, Tsagarakis, Stylianos, Cohen, Fredric J, Fleseriu, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090707/ http://dx.doi.org/10.1210/jendso/bvab048.1072

Ejemplares similares

MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study
por: Zacharieva, Sabina Z, et al.
Publicado: (2020)

Levoketoconazole in the treatment of patients with endogenous Cushing’s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS)
por: Pivonello, Rosario, et al.
Publicado: (2022)

SAT-452 Results from the Phase 3 Multicenter SONICS Study of Levoketoconazole: Subgroup Analysis of Cushing's Syndrome (CS) Patients with Diabetes Mellitus (DM)
por: Fleseriu, Maria, et al.
Publicado: (2019)

Levoketoconazole in the Treatment of Patients With Cushing’s Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study
por: Pivonello, Rosario, et al.
Publicado: (2021)

Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome
por: Geer, Eliza B., et al.
Publicado: (2020)

Correction to: Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome
por: Geer, Eliza B., et al.
Publicado: (2020)

OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3)
por: Biller, Beverly MK, et al.
Publicado: (2019)

Levoketoconazole treatment in endogenous Cushing’s syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes
por: Fleseriu, Maria, et al.
Publicado: (2022)

THU038 Osilodrostat Dosing In Cushing’s Disease: A Pooled Analysis Of The LINC Program
por: Newell-Price, John, et al.
Publicado: (2023)

Long-Term Control of Urinary Free Cortisol With Osilodrostat in Patients With Cushing’s Disease: Final Results From the LINC 2 Study
por: Fleseriu, Maria, et al.
Publicado: (2021)

PMON163 Effect of Osilodrostat on Androgens and Adrenal Hormones in Patients With Cushing's Disease: Long-Term Findings From the Phase III, Prospective LINC 3 Study
por: Fleseriu, Maria, et al.
Publicado: (2022)

Metyrapone Treatment in Endogenous Cushing’s Syndrome: Results at Week 12 From PROMPT, a Prospective International Multicenter, Open-Label, Phase III/IV Study
por: Nieman, Lynnette K, et al.
Publicado: (2021)

PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat
por: Biller, Beverly M K, et al.
Publicado: (2022)

THU035 Impact Of Surgery Or Medical Treatment With The Selective Glucocorticoid Receptor Modulator Relacorilant On Hypercoagulopathy In Patients With Cushing Syndrome
por: Simeoli, Chiara, et al.
Publicado: (2023)

MON-LB55 Biochemical Control of Most Patients Reverting to Injectable Long-Acting Somatostatin Receptor Ligands Is Achieved After One Dose: Results From the Phase 3, Randomized, Double Blind, Placebo-Controlled Optimal Study
por: Fleseriu, Maria, et al.
Publicado: (2020)

PMON166 Safety Comparison of 40- vs 60-mg/day Doses of Oral Octreotide Capsules for Treatment of Acromegaly in the CHIASMA OPTIMAL Trial
por: Elenkova, Atanaska, et al.
Publicado: (2022)

LBMON178 2nd Year Outcomes Of The Open-label Extension Of Chiasma Optimal, A Phase 3 Study Of Oral Octreotide Capsules In Acromegaly
por: Samson, Susan, et al.
Publicado: (2022)

THU041 Clinical Improvements In Patients With Cushing’s Disease Treated With Osilodrostat According To Urinary And Late-night Salivary Cortisol Levels: Pooled Analysis From LINC 3 And LINC 4
por: Biller, Beverly M K, et al.
Publicado: (2023)

THU032 Osilodrostat Is Effective And Well Tolerated In Patients Of Asian And Non-Asian Origin With Cushing's Disease: A Pooled Analysis From LINC 3 And LINC 4
por: Snyder, Peter J, et al.
Publicado: (2023)

THU033 High Prevalence Of Venous Thrombotic Events In Cushing’s Syndrome: Data From ERCUSYN
por: Isand, Kristina, et al.
Publicado: (2023)

SUN-463 Tumor Shrinkage with Preoperative Relacorilant Therapy in Two Patients with Cushing Disease Due to Pituitary Macroadenomas
por: Terzolo, Massimo, et al.
Publicado: (2019)

MON-LB57 Impact of Imputation Method and Response Cutoffs on Results From the Phase 3 OPTIMAL Study of Oral Octreotide Capsules in Adult Patients With Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2020)

One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2021)

SAT-256 The Ever Confusing Cushing’s Work Up: Is It Real? Is It Pseudo Cushing’s’? Or Could It Be Factitious
por: Ghalib, Luma, et al.
Publicado: (2020)

SUN-451 A Randomized-Withdrawal, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Selective Glucocorticoid Receptor Antagonist, Relacorilant, in Patients with Cushing Syndrome (GRACE Study)
por: Auchus, Richard, et al.
Publicado: (2019)

THU061 Treatment Patterns In Acromegaly: Analysis Of Real-World US Insurance Claims From The MarketScan(®) Database
por: Fleseriu, Maria, et al.
Publicado: (2023)

LBMON177 Dosing And Titration Of Osilodrostat In A Real-world Cohort Of US Patients With Endogenous Cushing's Disease: Analysis Of The ILLUSTRATE Study
por: Ioachimescu, Adriana Gabriela, et al.
Publicado: (2022)

LBMON176 Management, Safety, And Efficacy Of Osilodrostat Treatment In US Patients With Non-pituitary Cushing's Syndrome: Results From The ILLUSTRATE Study
por: Auchus, Richard Joseph, et al.
Publicado: (2022)

Hypercoagulability in ACTH-Dependent Cushing Syndrome
por: Singh Sumal, Amit Kartar, et al.
Publicado: (2021)

Occult Carcinoid Causes Cushing’s Syndrome
por: Meftali, Sabrina, et al.
Publicado: (2021)

THU021 Mysterious Resolution Of Cushing’s Disease
por: Whiteman, Daniel R, et al.
Publicado: (2023)

OR06-01 The Role of Germline Defects in Cushing’s Disease
por: Hernández-Ramírez, Laura C, et al.
Publicado: (2020)

SAT-277 A Fierce Presentation of Cushing Disease
por: Al Sabie, Farah Laith, et al.
Publicado: (2020)

Antisense Oligonucleotides as a Novel Therapy for Cushing’s Disease
por: Eltumi, Hanan, et al.
Publicado: (2021)

SAT-LB46 Depression as an Atypical Presentation of Cushing’s Disease
por: Pahwa, Dhivya, et al.
Publicado: (2020)

MON-328 Disorders of Glucose Metabolism in Cushing Syndrome in Uzbekistan
por: Narimova, Gulchekhra Djumaniyazovna, et al.
Publicado: (2020)

USP8 Somatic Mutations in Cushing’s Disease and Silent Corticotropinomas
por: Lamback, Elisa Baranski, et al.
Publicado: (2021)

Long-Term Corticotroph Function Following Cure of Cushing’s Syndrome
por: Schernthaner-Reiter, Marie Helene, et al.
Publicado: (2021)

ODP369 Weight Trajectory as a Predictor of Cushing's Disease
por: Thavaraputta, Subhanudh, et al.
Publicado: (2022)

ODP304 Cyclic Cushing Disease: A Diagnostic Challenge
por: Zubiran, Rafael, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eqs2rvpe1h9gbk6ki2ne4rq3dd